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results from HPS. Mean difference analysis across all 
assay results revealed wide differences between 0.01 and 
0.75 log IU/mL. RealTime showed the lowest intra-assay 
variation across genotypes 1–4 (25, 100, 1,000 IU/mL). 
There are substantial analytical differences between viral 
load assays clinicians should be aware of. These variations 
may have impact on clinical decisions for patients on HCV 
triple therapy and may argue for assay-specific decision 
points equivalent to reference values established in stud-
ies using HPS. A comparison of quantification is recom-
mended prior to a switch of assays during ongoing therapy.
Keywords HCV · Quantification · Viremia · COBAS · 
TaqMan · RealTime
Introduction
The treatment of hepatitis C virus infections has been com-
plicated due to low treatment success rates and/or high rates 
of treatment discontinuation in consequence of side effects. 
The former standard of care therapy for HCV-infected 
patients included a combination therapy with interferon 
and Ribavirin, both of which have nonspecific and largely 
unknown mechanisms of action. The development of directly 
acting antivirals (DAAs) has further improved new treatment 
options for patients who had been infected with the, formerly 
prognostically most unfavorable, genotype 1 [1].
However, those new treatment options may come along 
with high costs and an increased risk to develop severe 
treatment side effects. In this context, stopping rules were 
defined in the lower range of quantification to avoid unnec-
essary continuation of therapy [2]. For example, treatment 
with the NS3/4A protease inhibitor (PI) Boceprevir should 
be discontinued at week 12, if HCV RNA is ≥100 IU/mL, 
Abstract In the range of clinical decision points for 
response-guided therapy of HCV, there is still insufficient 
data concerning the conformity of quantification results 
obtained by different assays and their correlation with 
the HPS/CTM v2 assay which was used for initial clini-
cal studies. In a head-to-head comparison, assay accuracy 
and detection rates of six quantitative assays [artus HCV 
QS-RGQ, COBAS Ampliprep/COBAS TaqMan HCV v1/
v2, High Pure System/COBAS TaqMan (HPS), RealTime 
HCV, and Versant HCV1.0] were assessed by measuring 
WHO and PEI standards at dilution steps near clinical deci-
sion points. Detection rates and mean differences between 
assays were evaluated by analyzing twenty clinical samples 
at 10, 100, and 1,000 IU/mL. Ten replicates from speci-
mens with different HCV genotypes were used to analyze 
pan-genotypic intra-assay variation. At ≤25 IU/mL, Real-
Time demonstrated the highest detection rates. With 0.1 log 
difference when testing clinical samples, results obtained 
from the Versant and RealTime assays matched best with 
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or >1,000 at week 4 or 12 when using the HCV protease 
inhibitor Telaprevir, respectively [3]. Triple therapies with 
the more recently approved protease inhibitor Simeprevir 
require a control of viral load after week 4, with a cutoff 
of 25 IU/mL, and week 12, where viral load should be 
undetectable. These stopping rules are based on viral load 
data generated during the clinical phase II/III studies using 
the High Pure System (HPS)/COBAS TaqMan v2 (Roche) 
[4–7].
Qiagen artus HCV QS-RGQ, Roche COBAS 
AmpliPrep/COBAS TaqMan HCV versions 1.0 and 2.0, 
Abbott RealTime HCV assay, and the Siemens Versant 
HCV RNA version 1.0 are commercially available auto-
mated assays used for the quantification of HCV viral load 
while the Roche COBAS TaqMan HCV test for use with 
the High Pure System version 2.0 includes a manual extrac-
tion procedure. The assays were calibrated based on differ-
ent historical WHO standards and vary in sensitivity and 
quantification range (Table 1).
There is little information available concerning the com-
parability of results obtained by these six different assays 
in low viremic HCV samples, and there exists a particular 
interest to estimate the inter- and intra-assay variation at 
the lower end of the linear range of each assay, also with 
respect to different viral genotypes and the impact on 
patient management.
Materials and methods
HCV RNA viral load assays
Six commercially available quantitative HCV RNA assays 
were evaluated during this investigation: Qiagen artus 
HCV QS-RGQ (artus), Roche COBAS AmpliPrep/COBAS 
TaqMan HCV version 1.0 (CTM v1), Roche COBAS 
AmpliPrep/COBAS TaqMan HCV version 2.0 (CTM v2), 
Roche COBAS TaqMan HCV test for use with the High 
Pure System version 2.0 (HPS), Abbott RealTime HCV 
assay (RealTime), and the Siemens Versant HCV RNA ver-
sion 1.0 (Versant). Assay characteristics are summarized in 
Table 1.
Preanalytics
Serial dilutions of WHO and PEI standards and clinical 
specimens were prepared using HCV-negative Basematrix 
(Seracare Life Sciences; HCV negativity was confirmed 
by using the Abbott RealTime HCV assay). Afterward, 
these dilutions were aliquoted according to testing sched-
ule and number of assays investigated. All plasma samples 
were treated identically and underwent the same number of 
thawing cycles. Dilutions were prepared using HCV-nega-
tive Basematrix as mentioned above.
A total of five laboratories participated in this study. 
Samples were shipped on dry ice to the respective laborato-
ries, and successful delivery in a frozen state was confirmed.
Accuracy and detection rates using serially diluted WHO 
and PEI standards
Serial dilution panels at nominal concentrations of 1,000, 
500, 200, 100, 25, 10, and 5 IU/mL were prepared from the 
3rd WHO international standard (NIBSC code 06/100, gen-
otype 1a) and the German PEI reference HCV RNA stand-
ard (3443/04, Paul-Ehrlich-Institut, Germany, genotype 1a). 
Triplicates of panel members ranging from 1,000 to 25 IU/
mL were tested in a single run across the above-mentioned 
six different HCV viral load assays. For each panel mem-
ber, accuracy was determined using the observed median 
concentrations compared with the nominally assigned val-
ues from WHO and PEI.
Detection rates at extremely low viremic levels were 
assessed by testing triplicates of panel members within the 
range of 5–25 IU/mL.
Quantification of 20 clinical HCV genotype 1 samples
Archived leftover plasma specimens from 20 patients 
infected with HCV genotype 1 were serially diluted to con-
centrations of 1,000, 100, and 10 IU/mL based on previous 
routine quantification with RealTime, respectively. Three 
replicates of each sample were tested by each of the six 
HCV viral load assays. The differences between the vari-
ous assays and especially in comparison with the results of 
Table 1  Overview of assay 
characteristics as provided by 
the manufacturers at date of 
analysis
LLOQ lower limit of 
quantification, LOD limit of 
detection
artus CTM v1 CTM v2 HPS RealTime Versant
Manufacturer Qiagen Roche Roche Roche Abbott Siemens
Reference standard Acrometrix 1st WHO 2nd WHO 2nd WHO 2nd WHO 3rd WHO
Input volume (mL) 1.0 0.85 0.5 0.5 0.5 0.5
Target region 5′-UTR
LLOQ (IU/mL) 67.6 43 15 25 12 15
LOD (IU/mL) 36.2 15 15 ~9.3–16.1 12 15
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the HPS assay were estimated by mean difference analysis. 
Differences between quantification results for genotype 1a 
and 1b samples were investigated by scatter plot analysis, 
Mann–Whitney U test, t test after Kolmogorov–Smirnov 
and Shapiro–Wilk test for normality.
Quantification and intra-assay variation analysis using low 
viremic clinical samples of different HCV genotypes
Archived leftover plasma specimens from patients infected 
with HCV genotype 1a and 1b (n = 3 each), and genotype 
2, 3, and 4 (n = 1 each) were diluted to target concentra-
tions of 1,000, 100, and 25 IU/mL based on previous Real-
Time results, respectively. Each sample was analyzed in 10 
independent runs using one replicate per run across all six 
HCV viral load assays.
At each dilution of 1,000, 100, and 25 IU/mL, mean 
coefficients of variation (CV) were calculated if at least 
50 % of the clinical samples had results ≥LLOQ for atleast 
50 % of their replicates.
Range of uncertainty (RoU)
An additional statistical analysis for evaluating a range of 
uncertainty was based on precision and mean difference 
data of genotype 1 clinical samples compared with HPS 
assay results. The calculations for the lower and upper limit 
of the range of uncertainty were derived from two one-
sided confidence limit calculations approaching the clini-
cal decision point either from lower or higher viral loads as 
suggested in [8]:
(RL, limits of the range of uncertainty; COA, assay-specific 
equivalent of the clinical cutoff established by the reference 
assay; CV%, assay-specific coefficient of variation at the 
respective cutoff level; n, number of replicates). Calcula-
tions were assuming a 95 % confidence level resulting in a 
z value of 1.645.
Results
Evaluation of assay accuracy and detection rates using PEI 
and WHO standards
Figure 1 shows the correlation of the six investigated HCV 
RNA assays with the PEI and WHO standards across a 














concentrations. Differences between median assay results 
and nominal concentrations of the standard panel mem-
bers are listed in Table 2 and were found to be consist-
ently <0.5 log IU/mL only for RealTime (maximum 
0.36 log IU/mL) and Versant (maximum 0.49 log IU/mL). 
For the other assays, results differed up to 0.98 log IU/mL 
(CTM v2). artus results showed only small differences 
from nominal values at concentrations of 100 IU/mL and 
above but tended to either overestimate concentrations 
<100 IU/mL or HCV RNA was not detected or quantified. 
Different to median PEI standard results >100 IU/mL, the 
corresponding median WHO standard results tended to be 
quantified at lower values than expected by virtually all 
assays.
Fig. 1  Assay accuracy of all six assays analyzing panels of WHO 
and PEI standard replicates with nominal concentrations of 25–
1,000 IU/mL, respectively
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Detection rates of replicates of the WHO and PEI panel 
members with nominal concentrations of 25, 10, and 5 IU/
mL considerably varied across the assays investigated 
(Table 3). RealTime and Versant were able to quantify each 
of the six replicates of the WHO and PEI panel members at 
a nominal concentration of 25 IU/mL. In contrast, although 
detecting virtually all replicates, CTM v2 quantified only 
two and HPS quantified none out of six. At a concentration 
of 10 IU/mL, solely, CTM v1 and RealTime detected HCV 
RNA in all measured replicates, whereas the other assays 
did not detect HCV RNA in varying numbers of replicates. 
RealTime turned out to be the most sensitive assay com-
pared with the other systems by detecting four out of six 
PEI and WHO replicates at nominal concentrations of 5 IU/
mL as well as by showing the highest overall detection rate 
(89 %) at nominal concentrations of 5–25 IU/mL, followed 
by CTM v1 (78 %), HPS (67 %), Versant (56 %), artus 
(50 %), and CTM v2 (39 %).
Quantification of 20 clinical HCV genotype 1 samples
On the basis of 20 clinical HCV genotype 1 samples 
[genotype 1a (n = 10); genotype 1b (n = 10)], measured 
in triplicates, the extent of assay variation at the clinical 
decision points 100 and 1,000 IU/mL was demonstrated 
by mean difference analysis (Fig. 2). HPS, which was 
used as reference assay for establishing clinical decision 
points concerning stop or continuation of HCV treatment 
in clinical trials, showed the highest overall concordance 
with results obtained by RealTime or Versant with dif-
ferences <0.15 log IU/mL (Fig. 2; Table 4). Table 4 pro-
vides an overview of the quantification differences across 
all assays which ranged from 0.01 to 0.75 log IU/mL. 
With a difference of 0.29–0.75 log IU/mL, for instance, 
mean artus results tended to be measured clearly above 
the results found by other assays independent of the dilu-
tion analyzed. CTM v1 and CTM v2 showed only mar-
ginal discrepancies between each other but differed more 
than 0.2 log IU/mL from mean results measured by artus, 
RealTime, or HPS. An additional subanalysis identified 
statistically significantly higher concentrations for geno-
type 1b samples compared with genotype 1a samples 
when being analyzed with HPS, CTM v1, or CTM v2 
(Fig. 3).
Table 3  Analysis of assay detection rates at 5–25 IU/mL nominal 
concentration of PEI and WHO replicates





RealTime 6/6 6/6 4/6 89
CTM v1 6/6 6/6 2/6 78
HPS 6/6 4/6 2/6 67
Versant 6/6 3/6 1/6 56
artus 5/6 2/6 2/6 50
CTM v2 5/6 1/6 1/6 39
Assay minus HPS






Mean Difference [Log IU/ml]
1000 IU/ml nominal 100 IU/ml nominal
Fig. 2  Mean difference analysis in comparison with HPS results 
(measuring 20 clinical genotype 1 samples at clinical decision points 
with three replicates each)
Table 4  Mean difference analysis across all six investigated assays measuring 20 clinical genotype 1 samples (three replicates each) at clinical 
decision points 1000 IU/mL (left columns) and 100 IU/mL (right columns per assay)
Mean differences determined by calculating mean value of assay 1 minus mean value of assay 2
Assay 1 minus assay 2 Assay 2
Mean difference [log IU/mL] artus CTM v1 CTM v2 HPS RealTime Versant
Assay 1
 artus – 0.33 0.29 0.35 0.35 0.61 0.55 0.75 0.68 0.53 0.55
 CTM v1 −0.33 −0.29 – 0.02 0.06 0.29 0.27 0.42 0.38 0.20 0.26
 CTM v2 −0.35 −0.35 −0.02 −0.06 – 0.26 0.21 0.40 0.33 0.17 0.20
 HPS −0.61 −0.55 −0.29 −0.27 −0.26 −0.21 – 0.14 0.13 −0.08 −0.01
 RealTime −0.75 −0.68 −0.42 −0.38 −0.40 −0.33 −0.14 −0.13 – −0.22 −0.13
 Versant −0.53 −0.55 −0.20 −0.26 −0.17 −0.20 0.08 0.01 0.22 0.13 –
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In a further analysis, the ability of each assay to 
detect clinical samples at nominal HCV RNA concen-
trations of 10 IU/mL was tested on 60 replicates derived 
from the same 20 clinical samples (Table 5). CTM v2, 
RealTime, and Versant were able to detect all of the 
analyzed specimens. Two replicates were not detected 
by CTM v1 and HPS, respectively; artus missed ten 
replicates.
Quantification and analysis of assay variation within each 
assay by using low viremic clinical samples of different 
HCV genotypes
Figure 4 demonstrates the intra-assay variations for different 
concentrations of the HCV genotypes 1, 2, 3, and 4. Sam-
ples were tested in ten independent runs using one replicate 




















































































































































































































































































































































Fig. 3  Genotype 1a versus genotype 1b quantification based on 
means of 10 clinical samples with three replicates each [* or ** 
results are significantly different (p < 0.05) or (p < 0.01) as deter-
mined by unpaired Mann–Whitney and t test after Kolmogorov–
Smirnov and Shapiro–Wilk test for normality]
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respectively. CV% values across the tested genotypes and 
across the nominal concentrations 1,000, 100, and 25 IU/
mL ranged between 8 and 34 % for RealTime, 18–48 % for 
artus, 19–58 % for CTM v1, 17–108 % for CTM v2, 18–
48 % for HPS, and 22–65 % for Versant (Fig. 5). Overall, 
RealTime showed the highest precision across all target con-
centrations and across genotypes 1, 2, and 3. For genotype 
4, CV values obtained with artus and partially Versant were 
in a comparable low range as for RealTime (Fig. 5).
The less sensitive assays artus, CTM v1, and HPS failed 
to quantify the majority or even all replicates at 25 IU/mL 
across all tested genotypes 1–4. Additionally, Versant failed 
in quantifying most of genotype 2 replicates at 25 IU/mL. 
The majority of genotype 4 replicates were furthermore 
neither quantified by CTM v2 at 25 IU/mL nor by CTM v1 
and HPS at 100 IU/mL. Thus, RealTime was the only assay 
that quantified the majority of replicates at target concen-
trations of 25 IU/mL across all genotypes 1–4.
The differences in quantification across the assays as 
already shown in Fig. 2 were confirmed by these results 
(Fig. 4).
Range of uncertainty (RoU)
The RoUs for the different assays in relation to the stop-
ping rules evaluated with the HPS system are shown in 
Fig. 6 based on the data in Table 6. The reference points 
(indicated by black diamonds) refer to the equivalent 
HPS result considering assay-specific mean differences 
to HPS. The RoU exhibits assay-specific imprecision, 
differences in quantification compared with the assay 
used for evaluating the rules, and confidence limits for 
Table 5  Ability to detect HCV RNA in 20 clinical genotype 1 sam-
ples at 10 IU/mL (three replicates each)
* One or two replicates missing due to technical issues
** Six replicates missing due to lack of sample material
System N Not detected Positive < LLOQ ≥LLOQ
artus 60 10 22 28
CTM v1 58* 2 54 2
CTM v2 59* 0 23 36
HPS 54** 2 47 5
RealTime 60 0 30 30
Versant 60 0 22 38
Fig. 4  Intra-assay variations for absolute values as illustrated in box-
plot analysis (n = 3 samples for each of both subtypes 1a and 1b, 
n = 1 sample for genotypes 2–4, respectively; in total ten replicates 
per sample measured in 10 independent runs; no boxplots for artus, 
CTM v1, and HPS at 25 IU/mL due to insufficient number of quanti-
fied replicates)
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reporting results and guiding appropriate decisions [8]. 
Values beyond the upper and below the lower limits of 
the RoU refer to the values in relation to the HPS refer-
ence that provide at least 95 % confidence not to cross 
the clinical decision point. Consequently, test results 
within the RoU do not provide sufficient confidence to 
guide a decision and might be subject to further evalua-
tion [9].
Fig. 5  Mean coefficients of variation for ten replicates from 25 to 1,000 IU/mL nominal concentration and genotypes 1 (a), 2 (b), 3 (c), and 4 
(d)
Fig. 6  Range of uncertainty for different assays in relation to HPS at 
100 or 1,000 IU/mL [8]. Black bars represent areas of ≥95 % confi-
dence to not cross the decision threshold of the 618 100 IU/mL (a) or 
1,000 IU/mL (b) HPS value analogues. Diamonds refer to the assay-
specific HPS 619 equivalents. Gray bars refer to the RoU
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Discussion
Assay precision and accuracy are of great clinical rele-
vance since only one single measurement is used to predict 
whether a patient will or will not achieve SVR and there-
fore is eligible to continue an expensive antiviral therapy. 
Precision and accuracy especially in the low viremic range 
should be assured in order to properly determine viral 
loads. Furthermore, assay sensitivity plays a role in RGT 
since patients with undetectable HCV RNA at certain time 
points may be assigned to a shortened antiviral therapy.
Unfortunately, the above-mentioned clinical decision 
points were established using HPS, a manual assay that 
is rarely used in daily routine. Differences in HCV RNA 
quantification compared with HPS need to be evaluated in 
order to avoid inappropriate discontinuation of therapy or 
unnecessarily prolonged treatment.
In this analysis, assay accuracy was investigated using 
a serial dilution panel prepared from PEI and WHO stand-
ards at a nominal concentration range of 25–1,000 IU/mL. 
The assay results vary in the extent of deviation from the 
expected values. Potential contributing factors could be the 
adjustment of the assays to different reference standards 
but also differences in assay designs. Overall, the relation-
ship between expected and measured values for the individ-
ual assay is consistent across both PEI and WHO standard 
panels although the measured values at higher concentra-
tion levels are generally lower for WHO than for PEI stand-
ard replicates.
In addition, detection rates using low concentration 
members of the WHO and PEI panels (25, 10, 5 IU/mL) 
were compared across the assays. RealTime showed the 
highest overall detection rate of 89 % in this analysis, fol-
lowed by CTM v1 and HPS with 78 and 67 %, respectively. 
The lowest overall detection rate of 39 % was found using 
CTM v2. In contrast, when evaluating sensitivity in 20 
clinical genotype 1 samples at a target dilution of 10 IU/
mL, again RealTime but also CTM v2 and Versant showed 
100 % detection rates, while detection rates for artus, CTM 
v1, and HPS were lower (83, 97, and 96 %, respectively).
A recent publication by [10] likewise revealed a limited 
assay concordance of only 55 % comparing sensitivities 
of HPS, CTM v1, and CTM v2 in terms of detecting low 
HCV viremia at week 4 in RGT [10]. Similar differences 
between various assays were also found in other studies 
[11–13]. In 2013, Ogawa et al. [14] reported that despite 
undetectable HCV RNA in week 4 by CTM v1 indicat-
ing rapid virologic response (RVR), three patients (6.2 %) 
failed to achieve SVR. However, all patients with RVR 
according to the RealTime results achieved SVR. Further-
more in 2013, Sarrazin et al. [15] presented data support-
ing a RealTime-specific clinical cutoff of <12 IU/mL being 
equivalent to ‘undetected’ results by HPS for decisions on 
therapy truncation.
Differences in assay quantification were investigated 
by testing 20 clinical genotype 1 samples in triplicate at 
clinical decision points (target concentrations of 1,000 and 
100 IU/mL). Versant and RealTime results matched best 
with the results obtained by HPS, the assay used to estab-
lish clinical decision points in clinical studies with protease 
inhibitors. Mean difference analysis of the results of all 
assays revealed quantification differences between 0.01 and 
0.75 log IU/mL. Remarkably, throughout the entire study, 
artus measured the highest mean concentrations in the clin-
ical samples with the overall largest viral load difference 
(0.75 log IU/mL) being observed between artus and Real-
Time. This confirms similar results found by Drexler et al. 
[16]. Mean differences around 0.3–0.4 log IU/mL between 
RealTime and CTM v1 or CTM v2 confirm a previously 
reported trend [17–19]. Differences between genotype 1a 
and 1b quantification as obtained by HPS and CTM in this 
investigation were also observed by LaRue et al. [20] in 
2012 for CTM v1 though without statistical significance. 
Any impact on clinical decisions or other relevance due to 
the fact that all assays are standardized against genotype 1a 
standards [21, 22] may be addressed in future studies.
The comparison of six commercially available HCV RNA 
assays revealed substantial differences in assay precision at 
low viremic levels (25–1,000 IU/mL). RealTime demonstrated 
highest precision across all genotypes 1–4, which turned out 
to be superior compared with the other assays in genotype 1, 
2, and 3 replicates (Figs. 4, 5). This was especially apparent at 
lower viral loads <100 IU/mL. Only for genotype 4, artus and 
partially Versant showed comparable low CV values.
Table 6  Range of uncertainty 
characteristics
LL lower limit, UL upper limit; 
all numbers in IU/mL
100 IU/mL 1,000 IU/mL
Ref. value LL UL Ref. value LL UL
artus 355 225 836 4,074 2,890 6,900
Versant 102 68 210 1,202 830 2,182
RealTime 74 57 105 724 580 964
CTM v1 186 126 358 1,950 1,480 2,857
CTM v2 162 106 344 1,820 1,373 2,699
HPS 100 66 208 1,000 729 1,592
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The observed insufficient capability of Versant to quan-
tify the lowest concentration sample of genotype 2 and 
likewise of CTM v1, CTM v2, and HPS concerning the 
lower concentrations of genotype 4 samples is in line with 
previous reports of lower quantification of these genotypes 
by the respective assays [17, 19, 23, 24]. However, since 
only a single sample was tested for each of the genotypes 2, 
3, and 4, further investigation is needed.
As depicted above, viral load assays applied in daily 
routine measurements may considerably vary in terms of 
precision, quantification level, and detection rate. Several 
suggestions have been made to provide information about 
measurement uncertainties. The total analytic error (TAE) 
concepts describe important and well-regarded approaches 
combining random error, systematic error, and operational 
specifications. However, with regard to response-guided 
therapies, the bias of a laboratory result from a true value 
may not be as relevant as its relation to a clinical decision 
point. Therefore, we discussed our findings with the range 
of uncertainty concept (RoU) that specifically provides 
confidence information with regard to clinical decision 
points evaluated by reference methods. Recently, the RoU 
concept has been applied to HCV stopping rules [8], and 
here, we tested it for the first time using the results from a 
head-to-head comparison study.
The RoU illustrates and compares assay-specific impre-
cision and relative quantification differences compared to a 
reference, here HPS, in a single chart (Fig. 6). It also pro-
vides information on the confidence of a test result in rela-
tion to a cutoff evaluated with a different reference assay 
(HPS). The RoU estimates a laboratory’s specific prob-
ability of supporting appropriate decisions and mitigating 
the risk of inappropriate decisions. Assay-specific clinical 
decision points equivalent to the HPS reference values as 
indicated in Fig. 6 and retesting to reduce large RoUs may 
be considered to improve result reliability.
Conclusions
Evaluation and comparison of six commercially available 
HCV RNA assays revealed major differences in assay pre-
cision, quantification level, and detection rates. These may 
impact clinical decisions in particular related to stopping 
rules in response-guided therapy. Therefore, a compari-
son of quantification is recommended prior to a switch of 
assays during ongoing therapy. Thresholds were estab-
lished by HPS which is rarely used in clinical practice, 
and there is little information available concerning con-
cordance between HPS and other assays. In this analysis, 
HPS matched best with results generated by RealTime and 
Versant. Moreover, RealTime combined highest sensitivity 
with the highest precision across all analyzed genotypes 
expressed by the lowest mean coefficient of variation. This 
is of importance since treatment decisions in triple therapy 
are based on single measurements.
Emerging therapies with compounds like Simeprevir and 
Daclatasvir will still include stopping rules using cutoffs at 
25 IU/mL [25, 26]. Consequently, assays with reliable pre-
cision, accuracy, and sensitivity for quantification of HCV 
RNA in low level viremia will remain crucial to support 
optimal clinical decisions in HCV patient management.
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